UCB's zilucoplan shows no relevant effect in immune-mediated necrotizing myopathy (IMNM) | Proteins and Peptides

Hits: 92
· No unexpected safety findings and no relevant safety differences between zilucoplan and placebo were identified
· Phase 3 headline results for generalized myasthenia gravis (gMG) are unchanged expected in Q4 2021
BRUSSELS, Belgium I April 22, 2021 I Based on the initial results of a Phase 2 study investigating
zilucoplan in immune-mediated necrotizing myopathy (IMNM), UCB today announced that UCB has decided to not move forward with its IMNM development program. 
The phase 2 study with
zilucoplan, a peptide inhibitor of complement component 5 (C5), in immune-mediated necrotizing myopathy (IMNM) did not show a meaningful effect of
zilucoplan for people living with IMNM. No unexpected safety findings and no relevant safety differences between

Related Keywords

Japan ,Brussels ,Bruxelles Capitale ,Belgium ,Seanm Healey ,Iris Loew Friedrich , ,Belgiumi April ,Chief Medical Officer ,Half Year Results ,Generalized Myasthenia Gravis ,Biologics ,Protein ,Therapeutic Protein ,Peptide ,Recombinant ,Synthetic ,Biosimilar ,Biogeneric ,Biosuperior ,Binding Proteins ,ஜப்பான் ,பிரஸ்ஸல்ஸ் ,ப்ரூக்ஸெல்ஸ் தலைநகரம் ,பெல்ஜியம் ,கருவிழி குறைந்த பிரீட்ரிச் ,தலைமை மருத்துவ அதிகாரி ,பாதி ஆண்டு முடிவுகள் ,உயிரியல் ,